HRP980023A2 - Use of beta3-adrenergic receptor antagonists for the preparation of healing drugs - Google Patents
Use of beta3-adrenergic receptor antagonists for the preparation of healing drugsInfo
- Publication number
- HRP980023A2 HRP980023A2 HR9700584A HRP980023A HRP980023A2 HR P980023 A2 HRP980023 A2 HR P980023A2 HR 9700584 A HR9700584 A HR 9700584A HR P980023 A HRP980023 A HR P980023A HR P980023 A2 HRP980023 A2 HR P980023A2
- Authority
- HR
- Croatia
- Prior art keywords
- group
- alkyl
- substituted
- hydrogen
- phenyl
- Prior art date
Links
- 230000035876 healing Effects 0.000 title claims description 13
- 238000002360 preparation method Methods 0.000 title claims description 8
- 239000000674 adrenergic antagonist Substances 0.000 title description 5
- 102000016959 beta-3 Adrenergic Receptors Human genes 0.000 title description 5
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 title description 5
- 239000003814 drug Substances 0.000 title description 2
- 229940079593 drug Drugs 0.000 title description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 36
- 239000000556 agonist Substances 0.000 claims description 26
- 239000001257 hydrogen Substances 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 23
- 125000000524 functional group Chemical group 0.000 claims description 20
- -1 benzylthio Chemical group 0.000 claims description 18
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 17
- 239000013543 active substance Substances 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 12
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 10
- 208000027418 Wounds and injury Diseases 0.000 claims description 10
- 230000006378 damage Effects 0.000 claims description 10
- 208000014674 injury Diseases 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 238000011321 prophylaxis Methods 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 4
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 4
- 125000006766 (C2-C6) alkynyloxy group Chemical group 0.000 claims description 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 4
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000004244 benzofuran-2-yl group Chemical group [H]C1=C(*)OC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002431 hydrogen Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 208000028990 Skin injury Diseases 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 2
- 125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000005149 cycloalkylsulfinyl group Chemical group 0.000 claims description 2
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 claims description 2
- 125000005366 cycloalkylthio group Chemical group 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- RDJQCOBTKKAQAH-CTNGQTDRSA-N ethyl 2-[[(7r)-7-[[(2r)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]acetate Chemical group C1([C@@H](O)CN[C@@H]2CCC3=CC=C(C=C3C2)OCC(=O)OCC)=CC=CC(Cl)=C1 RDJQCOBTKKAQAH-CTNGQTDRSA-N 0.000 claims description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 2
- 150000002367 halogens Chemical group 0.000 claims description 2
- 210000003141 lower extremity Anatomy 0.000 claims description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 125000006678 phenoxycarbonyl group Chemical group 0.000 claims description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 2
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000002048 spasmolytic effect Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- OQZQLZWQJGEGBA-DAFXYXGESA-N 7-[[(2r)-2-hydroxy-2-phenylethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-ol Chemical compound C1([C@H](CNC2CC3=CC(O)=CC=C3CC2)O)=CC=CC=C1 OQZQLZWQJGEGBA-DAFXYXGESA-N 0.000 description 2
- OQZQLZWQJGEGBA-UHUGOGIASA-N 7-[[(2s)-2-hydroxy-2-phenylethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-ol Chemical compound C1([C@@H](CNC2CC3=CC(O)=CC=C3CC2)O)=CC=CC=C1 OQZQLZWQJGEGBA-UHUGOGIASA-N 0.000 description 2
- RDJQCOBTKKAQAH-FPOVZHCZSA-N Amibegron Chemical compound C1([C@@H](O)CN[C@H]2CCC3=CC=C(C=C3C2)OCC(=O)OCC)=CC=CC(Cl)=C1 RDJQCOBTKKAQAH-FPOVZHCZSA-N 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- OQZQLZWQJGEGBA-UHFFFAOYSA-N 7-[(2-hydroxy-2-phenylethyl)amino]-5,6,7,8-tetrahydronaphthalen-2-ol Chemical compound C1CC2=CC=C(O)C=C2CC1NCC(O)C1=CC=CC=C1 OQZQLZWQJGEGBA-UHFFFAOYSA-N 0.000 description 1
- CKZTVXSBPWEACF-UHFFFAOYSA-N 7-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-ol Chemical compound C1CC2=CC=C(O)C=C2CC1NCC(O)C1=CC=CC(Cl)=C1 CKZTVXSBPWEACF-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010061225 Limb injury Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- RDJQCOBTKKAQAH-UHFFFAOYSA-N amibegron Chemical compound C1C2=CC(OCC(=O)OCC)=CC=C2CCC1NCC(O)C1=CC=CC(Cl)=C1 RDJQCOBTKKAQAH-UHFFFAOYSA-N 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- KQLBCBGPWXUUBU-UHFFFAOYSA-N ethyl 2-[[7-[(2-hydroxy-2-phenylethyl)amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]acetate Chemical compound C1C2=CC(OCC(=O)OCC)=CC=C2CCC1NCC(O)C1=CC=CC=C1 KQLBCBGPWXUUBU-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- ZFLBZHXQAMUEFS-UHFFFAOYSA-N methyl 2-[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetate Chemical compound C1=CC(OCC(=O)OC)=CC=C1CC(C)NCC(O)C1=CC=CC(Cl)=C1 ZFLBZHXQAMUEFS-UHFFFAOYSA-N 0.000 description 1
- KSHIGWSTJJFGAN-QUCCMNQESA-N methyl 2-[[(7r)-7-[[(2r)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]acetate Chemical compound C1([C@@H](O)CN[C@@H]2CCC3=CC=C(C=C3C2)OCC(=O)OC)=CC=CC(Cl)=C1 KSHIGWSTJJFGAN-QUCCMNQESA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- JLVSPVFPBBFMBE-HXSWCURESA-O sphingosylphosphocholine acid Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H]([NH3+])COP([O-])(=O)OCC[N+](C)(C)C JLVSPVFPBBFMBE-HXSWCURESA-O 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9700584A FR2758460B1 (fr) | 1997-01-21 | 1997-01-21 | Utilisation des agonistes des recepteurs beta-3 adrenergiques pour la preparation de medicaments cicatrisants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP980023A2 true HRP980023A2 (en) | 1998-10-31 |
Family
ID=9502810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR9700584A HRP980023A2 (en) | 1997-01-21 | 1998-01-20 | Use of beta3-adrenergic receptor antagonists for the preparation of healing drugs |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6235793B1 (no) |
| EP (1) | EP0966276B1 (no) |
| JP (1) | JP2001508790A (no) |
| AR (1) | AR011546A1 (no) |
| AT (1) | ATE255889T1 (no) |
| AU (1) | AU5994198A (no) |
| BR (1) | BR9807288A (no) |
| CA (1) | CA2278220A1 (no) |
| DE (1) | DE69820422T2 (no) |
| FR (1) | FR2758460B1 (no) |
| HR (1) | HRP980023A2 (no) |
| NO (1) | NO326823B1 (no) |
| UY (1) | UY24848A1 (no) |
| WO (1) | WO1998031357A1 (no) |
| ZA (1) | ZA98484B (no) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2817257B1 (fr) | 2000-11-30 | 2009-03-20 | Sanofi Synthelabo | Cyclohexyl(alkyl)-propanolamines, leur preparation et compositions pharmaceutiques en contenant |
| WO2003106423A1 (ja) * | 2002-06-12 | 2003-12-24 | 住友製薬株式会社 | 環状アミン類およびそれを含む医薬組成物 |
| BRPI0720558B1 (pt) * | 2006-12-22 | 2018-10-23 | National Oilwell Varco Denmark I/S | tubo flexível |
| ATE498087T1 (de) | 2006-12-22 | 2011-02-15 | Nkt Flexibles Is | Flexibles rohr |
| US20240148701A1 (en) * | 2021-02-22 | 2024-05-09 | The University Of Sydney | Would healing methods |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0029320B1 (en) * | 1979-11-15 | 1985-07-10 | Beecham Group Plc | Secondary ethanol amines, their preparation and their use in pharmaceutical compositions |
| GB8528633D0 (en) * | 1985-11-21 | 1985-12-24 | Beecham Group Plc | Compounds |
| US5126324A (en) * | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
| US5502078A (en) * | 1991-05-28 | 1996-03-26 | Zeneca Limited | Chemical compounds |
| GB9308178D0 (en) * | 1993-04-21 | 1993-06-02 | Smithkline Beecham Plc | Novel compounds |
| US5578638A (en) * | 1993-11-05 | 1996-11-26 | American Cyanamid Company | Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists |
| JPH07228543A (ja) * | 1994-02-16 | 1995-08-29 | Fujisawa Pharmaceut Co Ltd | β３−アドレナリン作動薬の新規医薬用途 |
| US5962477A (en) * | 1994-04-12 | 1999-10-05 | Adolor Corporation | Screening methods for cytokine inhibitors |
| US5512592A (en) * | 1994-09-09 | 1996-04-30 | Wake Forest University | Method of producing cardiotonic effect and improving cardiac contractile function by administration of carnosine |
| US5597843A (en) * | 1995-06-07 | 1997-01-28 | Houghten Pharmaceuticals | Use of a substituted 1,3-benzodioxole to reduce a wasting condition |
| US5869450A (en) * | 1996-03-06 | 1999-02-09 | The Regents Of The University Of California | Anti-inflammatory compositions and method with corticotropin-releasing factor analogs |
-
1997
- 1997-01-21 FR FR9700584A patent/FR2758460B1/fr not_active Expired - Fee Related
-
1998
- 1998-01-20 AR ARP980100230A patent/AR011546A1/es unknown
- 1998-01-20 HR HR9700584A patent/HRP980023A2/hr not_active Application Discontinuation
- 1998-01-20 UY UY24848A patent/UY24848A1/es not_active Application Discontinuation
- 1998-01-21 DE DE69820422T patent/DE69820422T2/de not_active Expired - Fee Related
- 1998-01-21 AU AU59941/98A patent/AU5994198A/en not_active Abandoned
- 1998-01-21 WO PCT/FR1998/000105 patent/WO1998031357A1/fr active IP Right Grant
- 1998-01-21 BR BR9807288A patent/BR9807288A/pt not_active Application Discontinuation
- 1998-01-21 EP EP98903099A patent/EP0966276B1/fr not_active Expired - Lifetime
- 1998-01-21 AT AT98903099T patent/ATE255889T1/de not_active IP Right Cessation
- 1998-01-21 CA CA002278220A patent/CA2278220A1/en not_active Abandoned
- 1998-01-21 US US09/341,656 patent/US6235793B1/en not_active Expired - Fee Related
- 1998-01-21 JP JP53386198A patent/JP2001508790A/ja not_active Ceased
- 1998-01-21 ZA ZA98484A patent/ZA98484B/xx unknown
-
1999
- 1999-07-20 NO NO19993548A patent/NO326823B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU5994198A (en) | 1998-08-07 |
| DE69820422D1 (de) | 2004-01-22 |
| FR2758460B1 (fr) | 1999-12-31 |
| EP0966276A1 (fr) | 1999-12-29 |
| US6235793B1 (en) | 2001-05-22 |
| NO993548D0 (no) | 1999-07-20 |
| FR2758460A1 (fr) | 1998-07-24 |
| ATE255889T1 (de) | 2003-12-15 |
| NO993548L (no) | 1999-07-20 |
| AR011546A1 (es) | 2000-08-30 |
| JP2001508790A (ja) | 2001-07-03 |
| EP0966276B1 (fr) | 2003-12-10 |
| BR9807288A (pt) | 2000-03-21 |
| UY24848A1 (es) | 1998-04-21 |
| ZA98484B (en) | 1998-07-30 |
| CA2278220A1 (en) | 1998-07-23 |
| NO326823B1 (no) | 2009-02-23 |
| WO1998031357A1 (fr) | 1998-07-23 |
| DE69820422T2 (de) | 2004-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3676383B2 (ja) | 中枢性カンナビノイドレセプターアンタゴニストの欲求（ａｐｐｅｔｅｎｃｅ）を制御するための使用 | |
| EP1871368B1 (en) | Dihydropyridine compounds for neurodegenerative diseases and dementia | |
| JP2000507544A (ja) | 痛みの治療方法 | |
| JP2002529499A (ja) | 痛みの治療方法 | |
| US20050261356A1 (en) | Methods and compositions for the treatment of chronic lymphocytic leukemia | |
| KR20030036885A (ko) | Ｃｂ1 수용체 길항제와 시부트라민과의 조합물, 이를함유하는 약제학적 조성물 및 비만을 치료하기 위한 이의용도 | |
| JP2010511701A (ja) | 水素化ピリド（４，３−ｂ）インドール（異性体）に基づいた、発作を含む脳循環の急性および慢性疾患の治療のための手段、それに基づいた薬理学的手段、およびその使用のための方法 | |
| NL1007387C2 (nl) | Verbeteringen in of met betrekking tot de profylaxe van borstkanker. | |
| US8034828B2 (en) | Use of FGF inhibiting substituted 1,2,3 indolizine derivatives in the preparation of medicaments which can be used to treat diseases linked to pathological choroidal angiogenesis | |
| TWI225399B (en) | Use of saredutant and of its pharmaceutically acceptable salts for the preparation of medicinal products that are useful in the treatment or prevention of all mood disorders, adaptation disorders or mixed anxiety-depression disorders | |
| JP2009535410A (ja) | ピロロキノリンキノンおよびその使用 | |
| HRP980023A2 (en) | Use of beta3-adrenergic receptor antagonists for the preparation of healing drugs | |
| CZ285633B6 (cs) | Použití indolových derivátů pro výrobu léčiv a farmaceutický prostředek | |
| KR20210031922A (ko) | 간 질환의 가려움 증상 치료 | |
| JP2013035873A (ja) | 神経障害の治療における選択的オピエート受容体調節物質の使用 | |
| MXPA99006658A (en) | Use of agonists of adrenergic beta-3 receptors for preparing wound-healing medicines | |
| JP4287523B2 (ja) | 抗腫瘍剤 | |
| JPH10512260A (ja) | 成長ホルモン作用の阻害方法 | |
| JP2003504396A (ja) | マクロライド化合物の新規用途 | |
| JPH0256426A (ja) | 虚血性脳障害処置剤 | |
| MXPA99006785A (en) | Use of central cannabinoid receptor antagonists for regulating appetence | |
| EP1671631A2 (en) | Compositions for the treatment of chronic lymphocytic leukemia | |
| KR20060059022A (ko) | 호박산 수마트립탄을 함유하는 약제학적 조성물 | |
| RU2000124320A (ru) | Фармацевтический препарат, включающий агонист рецепторов ангиотензина ii типа 2, и его применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| ODBI | Application refused |